Daewon Pharmaceutical's latest marketcap:
As of 06/18/2025, Daewon Pharmaceutical's market capitalization has reached $210.29 M. According to our data, Daewon Pharmaceutical is the 19695th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 210.29 M |
| Revenue (ttm) | 432.13 M |
| Net Income (ttm) | 7.51 M |
| Shares Out | 21.43 M |
| EPS (ttm) | 0.35 |
| Forward PE | 23.61 |
| Ex-Dividend Date | 12/27/2024 |
| Earnings Date | 08/13/2025 |
Daewon Pharmaceutical's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/18/2025 | ₩210.29 M | -5.33% | 19695 |
| 12/30/2024 | ₩305.43 B | -7.98% | 18852 |
| 12/28/2023 | ₩331.93 B | -15.58% | 17387 |
| 12/29/2022 | ₩393.2 B | 14.64% | 15326 |
| 12/30/2021 | ₩343 B | -9.91% | 16704 |
| 12/30/2020 | ₩380.71 B | 13.65% | 13673 |
| 12/30/2019 | ₩335 B | 10.32% | 12958 |
| 12/28/2018 | ₩303.66 B | -20.39% | 12383 |
| 12/28/2017 | ₩381.46 B | 11.92% | 12095 |
| 12/29/2016 | ₩340.83 B | 13.48% | 11488 |
Company Profile
About Daewon Pharmaceutical Co., Ltd.
Daewon Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company specializing in the manufacturing and distribution of medicines and medical supplies. Established in 1958 and headquartered in Seoul, the company serves both domestic and international markets.
Key Products
- Oramin-F Soft Cap: A multivitamin supplement.
- Pelubi Tablet: A NSAID product for pain relief.
- Freefol-MCT Inj.: A microemulsion propofol for anti-exogenous infectious bacteria.
- Megex-I Susp: A subalimentation supplement for cancer patients.
- Trigel Susp: A therapy for gastritis and duodenal ulcers.
- Renamezin Cap: A spherical carbonaceous adsorbent for chronic kidney disease.
Market Reach
The company exports its products to approximately 40 countries, with a strong presence in:
- Asia
- Central and South America
- The Middle East
- CIS (Commonwealth of Independent States)
- Africa
Therapeutic Areas
Daewon Pharmaceutical provides medicines for various medical conditions, including:
- Circulatory disorders
- Respiratory ailments
- Antibiotic treatments
- Chemotherapy
- Psychoneurosis
Frequently Asked Questions
-
What is Daewon Pharmaceutical's (KRX-003220) current market cap?As of 06/18/2025, Daewon Pharmaceutical (including the parent company, if applicable) has an estimated market capitalization of $210.29 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Daewon Pharmaceutical (KRX-003220) rank globally by market cap?Daewon Pharmaceutical global market capitalization ranking is approximately 19695 as of 06/18/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.